Back to search
FDAFDA · Food and drugs·Recall number D-166-2013

Hydrocodone Bitartrate and Acetaminophen Tablets, USP, 10 mg/500 mg; 100 Tablets (5 x 20), 5 cards each containing 20 blistered tablets per carton, Rx only; Manufactured for: Qualitest Pharmaceuticals, Huntsville, AL 35811, Pkg by & Distributed by UDL Laboratories, Inc., Rockford, IL 61103; NDC 51079-254-21.

Published February 27, 2013 · Recall initiated: December 14, 2012

Summary

FDA records drug Class I recall D-166-2013, published February 27, 2013 and initiated December 14, 2012. Recalling firm: Mylan Institutional, Inc. (d.b.a. UDL Laboratories); Status: Terminated; Reported quantity: 3,407 cartons; Lot: Lot #: 3037841, 3040859, 3042573, Exp 12/13. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent (Multiple Ingredient) Drug: Oversized tablets resulting in superpotent assays of both the hydrocodone and acetaminophen components.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Distributor
Nationwide
Lot
Lot #: 3037841, 3040859, 3042573, Exp 12/13
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Hydrocodone Bitartrate and Acetaminophen Tablets, USP, 10 mg/500 mg; 100 Tablets (5 x 20), 5 cards each containing 20 blistered tablets per carton, Rx only; Manufactured for: Qualitest Pharmaceuticals, Huntsville, AL 35811, Pkg by & Distributed by UDL Laboratories, Inc., Rockford, IL 61103; NDC 51079-254-21. recalled?

Yes. FDA published recall D-166-2013 on February 27, 2013. Reported hazard: Superpotent (Multiple Ingredient) Drug: Oversized tablets resulting in superpotent assays of both the hydrocodone and acetaminophen components.

What should I do if I have this product?

Voluntary: Firm initiated · Letter